New

Controls & Reference Materials

Seraseq® Compromised FFPE Tumor DNA RM

Material Number 0710-1492
Size 1 x 10 µm
Inventory Status In Stock
Unit EA

Comprehensive genomic profiling (CGP) is an important part of an integrated clinical management of cancer patients, where cancer patients harboring variants/biomarkers of clinical utility are determined by highly multiplexed targeted NGS assay testing. Precise analysis of these patient samples requires high quality sample-to-result assay workflow controls to guide and validate the accurate identification of these actionable variants.

LGC SeraCare has developed a highly multiplexed Compromised FFPE Tumor DNA reference material imbibing “patient-like” characteristics to support end-to-end NGS workflows performed by clinical labs in the analysis of cancer patient samples. This product consists of 17 genes and 34 variants, incorporating all variant types – SNVs, INDELs, CNVs, and SVs. These variants were precisely quantitated by digital PCR and targeted NGS against a single well-characterized genomic background (GM24385).

  • Highly multiplexed FFPE Tumor DNA reference material
  • Contains 34 variants in 17 genes
  • All variant types – SNVs (18), INDELs (10), CNVs (3) and SVs (3)
  • For use in sample-to-result NGS workflows to analyze for mutation-positive variants in patient samples
  • Manufactured in GMP-compliant ISO 13485 certified facility
Gene List
ATK1EGFRMYCCD74-ROSI
ALKERBB2NRASNCOA4-RET
BRAFKITPIK3CAEML4-ALK
BRCA1KRASTP53 
BRCA2MET  

Seraseq Compromised FFPE Tumor DNA Reference Material

Doc type
Product Sheet

Compromised FFPE Tumor DNA Reference Material

Doc type
Package Insert

Compromised FFPE Tumor DNA Reference Material

Doc type
Product Report
Lot #
10499589
Product Specifications - Compromised FFPE Tumor DNA RM
# of genes 17
Size 10 µm
Format FFPE
DNA Yield >100 ng*

*QIAamp FFPE Tissue DNA Kit